Current and emerging pharmacotherapeutic options for smoking cessation

Kristin Carson, Malcolm Brinn, Thomas Robertson, Rachada To-A-Nan, Adrian Esterman, Matthew Peters, Brian Smith

    Research output: Contribution to journalReview articlepeer-review

    12 Citations (Scopus)


    Tobacco smoking remains the single most preventable cause of morbidity and mortality in developed countries and poses a significant threat across developing countries where tobacco use prevalence is increasing. Nicotine dependence is a chronic disease often requiring multiple attempts to quit; repeated interventions with pharmacotherapeutic aids have become more popular as part of cessation therapies. First-line medications of known efficacy in the general population include varenicline tartrate, bupropion hydrochloride, nicotine replacement therapy products, or a combination thereof. However, less is known about the use of these products in marginalized groups such as the indigenous, those with mental illnesses, youth, and pregnant or breastfeeding women. Despite the efficacy and safety of these first line pharmacotherapies, many smokers continue to relapse and alternative pharmacotherapies and cessation options are required. Thus, the aim of this review is to summarize the existing and developing pharmacotherapeutic and other options for smoking cessation, to identify gaps in current clinical practice, and to provide recommendations for future evaluations and research.

    Original languageEnglish
    Pages (from-to)85-105
    Number of pages21
    JournalSubstance Abuse: Research and Treatment
    Publication statusPublished - 2013


    • Bupropion
    • Champix
    • Nicotine
    • Nicotine patches
    • Pharmacotherapeutic
    • Pharmacotherapy
    • Smoking
    • Smoking cessation
    • Varenicline tartrate
    • Zyban


    Dive into the research topics of 'Current and emerging pharmacotherapeutic options for smoking cessation'. Together they form a unique fingerprint.

    Cite this